Abstract:Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an important curative therapy for patients with leukemia. However, relapse remains the leading cause of death after transplantation. In recent years, substantial progress has been made by Chinese physicians in the field of establishment of novel transplant modality, patient selection, minimal residual disease (MRD) monitoring, and immunological therapies, such as modified donor lymphocyte infusion (DLI) and chimeric antigen receptor T (CART) cells, as well as MRD-directed intervention for relapse. Most of these unique systems are distinct from those in the Western world. In this consensus, we reviewed the efficacy of post-HSCT relapse management practice from available Chinese studies on behalf of the HSCT workgroup of the Chinese Society of Hematology, Chinese Medical Association, and compared these studies withthe consensus or guidelines outside China. We summarized the consensus on routine practices of post-HSCT relapse management in China and focused on the recommendations of MRD monitoring, risk stratification directed strategies, and modified DLI system. This consensus will likely contribute to the standardization of post-HSCT relapse management in China and become an inspiration for further international cooperation to refine global practices.

Reply to “reply to ‘the Correlation Between Cotransplantation of Mesenchymal Stem Cells and Higher Recurrence Rates in Hematologic Malignancy Patients: Outcome of a Pilot Clinical Study’ by Ning H Et Al.” by Behre Et Al.

The Authors Reply:

Reply to Huang Et Al.

Geng et al. reply

Umbilical Cord–Derived Mesenchymal Stromal Cells For Prevention of Chronic Graft-vs-Host Disease—Reply

Corrigendum to "re: Pathologic Complete Responses, Long-Term Outcomes, and Recurrence Patterns in HER2-low Vs. HER2-zero Breast Cancer after Neoadjuvant Chemotherapy: Several Issues about HER2 Expression and Neoadjuvant Chemotherapy in Breast Cancer" [eur J Cancer 180 (2023) 184-185].

Corrigendum: Comparison of Clinical Outcomes Between Cone Beam CT-guided Thermal Ablation and Helical Tomotherapy in Pulmonary Metastases from Hepatocellular Carcinoma

Corrigendum: Immune Tolerance Induced by Hematopoietic Stem Cell Infusion after HLA Identical Sibling Kidney Transplantation

Response to Chen et al and the Accompanying Commentary

Corrigendum: Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib

Corrigendum: Long-term oncologic outcomes following breast cancer surgery in adolescents and young adults: a single-center retrospective analysis

Author Correction: Suppression of M 6 A Reader Ythdf2 Promotes Hematopoietic Stem Cell Expansion

Correction: Hematopoietic stem cell transplantation activity in China 2022–2023. The proportions of peripheral blood for stem cell source continue to grow: a report from the Chinese Blood and Marrow Transplantation Registry Group

Corrigendum: Effect of Carbon Ion Radiation Induce Bystander Effect on Metastasis of A549 Cells and Metabonomic Correlation Analysis

Correction: Allogeneic Hematopoietic Stem Cell Transplantation Should Be in Preference to Conventional Chemotherapy As Post-Remission Treatment for Adults with Lymphoblastic Lymphoma

Reply to Sonnenberg et al

Zhu et al. Reply:

Erratum: A comparative gene-expression analysis of CD34+ hematopoietic stem and progenitor cells grown in static and stirred culture systems

Correction: Zhang et al. Clinical Management of Low Anterior Resection Syndrome: Review of the Current Diagnosis and Treatment. Cancers 2023, 15, 5011

The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in China